SUMMARY
Purpose: To analyze the prevalence and morphometric characteristics of macular hole (MH) development in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab. Methods: Patients diagnosed of neovascular AMD from January 2009 to December 2010 have been analyzed. Measurement of visual acuity and optical coherence tomography (OCT) were scheduled. Results: Two hundred and thirteen eyes (patients) with exudative AMD were analyzed. Development of MH was evidenced in 4 eyes (1,9%) Discussion: MH formation is a severe complication in patients with CNV treated with ranibizumab, frequently undervalued, which interfers with final outcome.